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Abstract
Background: A rural region in south-west Spain has one of the highest lung cancer incidence rates of the country,
as revealed by a previous epidemiological 10-year follow-up study. The present work was undertaken to ascertain
the role of CYP1A1 gene polymorphisms and their interaction with tobacco smoking in the development of the
disease in this location.
Methods: One-hundred-and-three cases of lung cancer and 265 controls participated in the study. The participants
were screened for the presence of four CYP1A1 polymorphisms, namely MspI, Ile462Val, T3205C, and Thr461Asn.
Lung cancer risk was estimated as odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic
regression models adjusting for age, sex, and smoking.
Results: The distribution of the variant CYP1A1 alleles was different from that described for other Caucasian
populations, with CYP1A1*2A showing an uncommonly high frequency (p < 0.01). The CYP1A1*2B allele (carrying
MspI and Ile462Val mutations) was strongly associated with high lung cancer risk (OR = 4.59, CI:1.4-12.6, p <0.01).
The Ile462Val polymorphism was also shown to increase the risk for the disease (OR = 4.51, CI:1.8-11.9; p <0.01)
and particularly for squamous-cell (OR = 5.01; CI: 1.6-14.3, p < 0.01) and small-cell lung carcinoma (SCLC) (OR =
6.97, CI: 1.2-81.3; p = 0.04). Moreover, the Thr461Asn polymorphism was found to be associated with SCLC in a
Caucasian population for the first time to our knowledge (OR = 8.33, CI: 1.3-15.2, p = 0.04).
Conclusion: The results suggest that CYP1A1 polymorphisms contribute to increase lung cancer susceptibility in an
area with an uncommon high incidence rate.
Background
I nt h el a t ee i g h t i e s ,ag r o u po fo n c o l o g i s t sw o r k i n ga t
the Merida hospital, which is located in an agricultural
region situated in south-west Spain, started to notice
the unusually high number of lung cancer patients being
diagnosed. This prompted the creation of a local lung
cancer registry in accordance with the guidelines issued
by the International Agency for Research on Cancer
(IARC) and the International Association of Cancer
Registries (IACR). Quite shockingly, in a 10-year follow-
up this registry revealed one of the highest standardized
incidence rates of male lung cancer in Spain (58 cases
per 100 000 inhabitants in the 1986-1990 period, Caba-
nillas et al., unpublished observations). This figure,
which has remained high over the years that followed
[1], is much higher than the Spanish mean (43 cases/
100 000 inhabitants in the same period) and similar to
that of heavily industrialized and mining areas of north-
ern Spain.
Tobacco smoking has long been established as a risk
factor for lung cancer, even though fewer than 20% of
smokers develop the disease. Tobacco smoke contains
several carcinogens including polycyclic aromatic hydro-
carbons (PAHs), N-nitrosamines, and heterocyclic
amines [2], which undergo biotransformation via a num-
ber of metabolic routes. Cytochrome P450 (CYP)
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any medium, provided the original work is properly cited.isozymes activate these environmental pollutants to yield
highly reactive substances that bind to DNA, forming
adducts involved in the initiation of carcinogenesis [3,4].
Within the CYP system, CYP1A1 plays a major role as a
carcinogen activating enzyme. Unlike most CYP
enzymes, CYP1A1 is mainly expressed in extrahepatic
tissues, including the lung, where it metabolizes and is
markedly induced by PAHs [5,6]. Elevated CYP1A1
inducibility is associated with pulmonary PAH-related
DNA adduction [7] and high lung cancer risk [8,9].
Both the formation of these PAH-DNA adducts and
CYP1A1 expression in human lung tissue are highly
variable [10-13], possibly due to differing exposure to
environmental factors and to genetic polymorphisms
affecting the CYP1A1 gene locus.
An u m b e ro fCYP1A1 allele variants have been asso-
ciated with a higher inducibility and/or activity of the
enzyme, and hence higher pulmonary PAH-related DNA
adduction [7]. The first variant allele identified was
CYP1A1*2A (also known as MspI or m1 polymorphism)
and is found in 5% of Caucasians [14]. CYP1A1*2C
(Ile462Val or m2 polymorphism) is rare in Caucasians
and is mostly detected in linkage disequilibrium with
CYP1A1*2A [15]. The combination of both variants is
referred to as CYP1A1*2B ( f o rac o m p l e t el i s to f
CYP1A1 variant alleles see http://www.cypalleles.ki.se/
cyp1a1.htm). CYP1A1*3, consisting of a T3205C base
change (m3), also seems to confer enhanced enzyme
activity, although it is extremely uncommon in Cauca-
sians [14]. Finally, CYP1A1*4, a Thr461Asn (m4)amino
acid change that is detected in Caucasians with a fre-
quency of roughly 3%, has also been related to greater
enzyme catalytic efficiency [16].
These CYP1A1 polymorphisms have been extensively
studied with regard to lung cancer risk. However,
whereas some studies report increased risk in the pre-
sence of some of the mutations [17-21], there are many
other contradictory results and ethnic differences
[22-25], which has led to the perception that the find-
ings have been inconsistent [22].
The goal of the present study was therefore to deter-
mine whether CYP1A1 polymorphisms and their inter-
action with smoking may play a role in the
aforementioned extraordinarily elevated lung cancer
incidence in our population.
Methods
Study design
We conducted a case-control study in the health district
of Merida (Spain), which gives health coverage to a
population of 156 000, in order to establish whether
CYP1A1 polymorphisms may contribute to the elevated
prevalence of lung cancer in the region. Cases were
Caucasian patients first diagnosed with lung cancer at
the Merida hospital. This hospital is the only referral
cancer health centre for the region, and thus all cancer
disease diagnoses and patient follow-up are carried out
in this hospital. The diagnosis was based on histological
analyses of endoscopic biopsies and/or surgical resection
specimens. The patients were selected by non-probabil-
ity consecutive sampling with no restrictions for age,
sex, or tumour grade (Eastern Cooperative Oncology
Group, ECOG). Information on tumour extension, grade
and histological type was extracted from clinical records
and the files of the Merida Hospital Pathological Anat-
omy Service. Controls were cancer-free individuals
admitted to the Hospital Trauma Service and matched
to the cases by sex and age (± 5 years). All the partici-
pants were interviewed by trained Hospital personnel to
collect data on anthropometric characteristics, family
history and details of smoking habits.
Each subject was aware of the purpose of the study,
and gave oral and written informed consent for partici-
pation. The study was approved by the Ethics Commit-
tee of the University of Extremadura (Badajoz, Spain)
and was conducted in accordance with the Declaration
of Helsinki and its subsequent revisions
Genotyping
Blood samples were drawn from all participants and
immediately stored at -80°C until genotype analysis.
Genomic DNA was isolated from peripheral blood leu-
kocytes in 2-ml aliquots of the whole-blood sample with
a Qiagen blood midi kit (Qiagen Inc., Chatsworth, CA).
The MspI polymorphism was detected by PCR ampli-
fication followed by digestion with MspI restriction
enzyme as described by Cascorbi et al [26]. In order to
identify the Ile462Val and Thr461Asn mutations, a sin-
gle PCR amplicon was digested with BsrDI or BsaI
restriction enzymes, respectively [26]. Finally, the
T3205C polymorphism was detected following the
method reported by Hayashi and co-workers [27].
Previously sequenced samples were used as negative and
positive controls to rule out possible genotyping errors.
Likewise, the analysis all mutant homozygous samples and
20% of heterozygotes was duplicated and confirmed by
direct sequencing with 100% concordance (ABI3700 DNA
Analyzer; Perkin-Elmer/Applied Biosystems).
Statistical analyses
Power analysis retrieved a sample size of 94 cases and
94 patients necessary to detect an OR of 4 with a dou-
ble-tale significant level of a =0 . 0 5a n dc
2 =0 . 8 0 ,
assuming a global prevalence of heterozygotes for the
CYP1A1*2B and CYP1A1*2A alleles of 6.4% and 10.5%
respectively in Caucasian population [14].
Hardy-Weinberg equilibrium was tested for the differ-
ent CYP1A1 genotype frequencies in controls using
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In order to estimate the association between CYP1A1
variant alleles and lung cancer risk, a stepwise condi-
tional multiple logistic regression analysis was per-
formed with enrolled threshold a ≤ 0.20 and excluded
threshold a ≥ 0.05. The odds ratios (OR) with 95% con-
fidence intervals (CI) were thus calculated for each sig-
nificant risk factor. The models were adjusted for age,
sex, and cumulative tobacco consumption unless stated
otherwise. To avoid collinearity in the regression analy-
sis of the risk, and to enhance the statistical power of
the study, participants were divided into 4 genotype
groups according to the mutations carried. Group 1
consisted of the homozygous wild-type subjects
(CYP1A1*1/*1 genotype), Group 2 of subjects with the
MspI polymorphism (CYP1A1*1/*2A genotype), Group 3
of subjects with the Ile462Val mutation (CYP1A1*1/*2B,
CYP1A1*3/*2B, and CYP1A1*1/*2C genotypes), and
Group 4 of subjects with the Thr461Asn polymorphism
(CYP1A1*1/*4, CYP1A1*4/*4, and CYP1A1*2A/*4 geno-
types). The CYP1A1*1/*3 genotype was present in only
one case and two controls, and hence was eliminated
from the statistical analysis.
Cumulative tobacco consumption was quantified in
pack-years (defined as the number of packs of 20 cigar-
ettes smoked per day multiplied by the number of years
of smoking). The median of pack-years (50) was used as
cut-point for the stratification analysis. Subjects with a
pack-years value above 50 were considered heavy smo-
kers, subjects with values less than or equal to 50 mod-
erate smokers, and subjects with values less than 0.2
pack-years or who had never smoked were considered
non-smokers. Finally, subjects who had quit smoking
more than a year before the diagnosis (cases) or inter-
vention (controls) were regarded as previous smokers.
Quantitative variables such as age and cumulative
tobacco consumption (pack-years) were compared by
Student’s t-test. The chi-squared or Fisher’s exact tests
were used to compare categorical variables between
cases and controls (sex, smoking status, family history of
tumours, and allele and genotype frequencies).
Statistical analyses were conducted using the SPSS
software package version 9.0 for Windows (SPSS Chi-
cago, IL) and Statistical Analysis System version 9.1.3
(SAS Institute). In all instances, results were considered
significant at the two-sided p < 0.05 level.
Results
In the period of study, 427 subjects (115 cases and 312
controls) fulfilled the inclusion criteria. Fifty-nine of
them rejected participating in the study, therefore a
total of 368 individuals (103 cases and 265 controls)
were finally included. Mean age was 2.1 years lower in
control subjects (66.0 ± 10.7 vs 63.9 ± 12.9; p = 0.019),
whereas the percentage of men was similar between
both study groups (95.1% vs 95.9%; p = 1).
Table 1 shows that the proportion of current and
heavy smokers and the number of pack-years was signif-
icantly higher among cases (p < 0.001). In addition,
patients who were former smokers had quit smoking
more recently than controls (11.3 ± 9.6 vs 17.2 ± 12.1
years, p = 0.03). Lastly, a history of first-degree family
cancer was also reported more frequently among cases
(p < 0.001, Table 1).
With regard to the genotype analysis, the frequencies
of the 4 mutations in the control group (9.9%, 1.1%,
0.5%, and 3.9% for MspI, Ile462Val, T3205C, and
Thr461Asn, respectively) were similar to those pre-
viously described in Caucasians [26]. However, the dis-
tribution of the variant alleles was different. In the
control group, CYP1A1*2A had a frequency that was
uncommonly high for Caucasians (8.5%, p <0 . 0 1vs
other Caucasian populations [14,26]). In contrast,
CYP1A1*2B and CYP1A1*2C alleles were under-repre-
sented although the difference did not reach statistical
significance.
The analysis of differences between cases and controls
showed the CYP1A1*2B allele to be associated with
increased lung cancer risk (OR = 4.59; CI: 1.4-12.6,
p < 0.01, Table 2).
Nine different CYP1A1 genotypes were detected in the
study population (Table 3). Their frequencies were con-
sistent with Hardy-Weinberg equilibrium in the control
Table 1 Characteristics of the 103 lung cancer patients
and 265 controls.
Cases, N (%) Controls, N p value
Smoking status < 0.001
ξ
Never 6 (5.8) 69 (26.1)
Former 36 (34.9) 128 (48.2)
Current 61 (59.2) 68 (25.7)
Pack-years (PY) 61.2 ± 28.5 29.9 ± 21.4 < 0.001
‡
Current and Former Smoking < 0.001
ξ
Moderate (≤50 PY) 30 (29.1) 137 (51.8)
Heavy (>50 PY) 67 (65) 59 (22.1)
Family history of tumours < 0.001
ξ
Yes 47 (45.6) 66 (24.9)
No 56 (54.4) 199 (75.1)
Histological tumour type
Squamous cell carcinoma 49 (47.6)
Large cell carcinoma 23 (22.3)
Adenocarcinoma 16 (15.5)
Small cell carcinoma 15 (14.6)
* Plus-minus values are means ± standard deviation. Because of rounding,
percentages may not total 100.
‡ Student’s t test.
ξ Pearson’s c
2 analysis.
gFirst-degree family.
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2=0 . 5 8 ,p = 0.91). A total of 189 (71.3%) con-
trols and 68 (66.0%) cases were carriers of the homozy-
gous wild-type genotype. The two commonest variant
genotypes were CYP1A1*1/*2A and CYP1A1 *1/*2B,t h e
latter being four times more frequent in cases (10.7%)
than in controls (2.6%, p < 0.01, Table 3). There were
no subjects who were homozygous for the CYP1A1*2A,
*2B,o r*3 alleles, and only 1 case and 1 control carried
the CYP1A1*4/*4 genotype.
After adjusting for age, sex, and smoking, those sub-
jects harbouring the Ile462Val mutation (*2B/*1, *2B/*3
and *2C/*1 genotypes) were at higher lung cancer risk,
whether considering all cases combined (OR = 4.51, CI:
1.8-11.9; p < 0.01), or the small-cell lung carcinoma
(SCLC) (OR = 6.97, CI: 1.2-81.3; p = 0.04), and squa-
mous-cell carcinoma subgroups (OR = 5.01, CI: 1.6-
14.3; p < 0.01) (Table 4). Finally, subjects carrying the
Thr461Asn polymorphism (CYP1A1*4 allele) were also
associated with a higher risk of SCLC (OR = 8.33, CI:
1.1-15.2, p = 0.04) (Table 4).
After stratification of the population according to
cumulative tobacco dose (non-smokers, moderate smo-
kers, and heavy smokers), none of the 4 different
genotype groups analyzed was significantly associated to
higher lung cancer risk. In moderate smokers the
observed OR (CI) were 0.61 (0.03-2.0), 3.98 (0.3-43.8)
and 1.11 (0.1-8.0) for subjects carrying the MspI, Ile462-
Val and Thr461Asn polymorphisms, respectively. With
regard to heavy smokers, OR (CI) values for the same
genotype groups were 1.08 (0.1-7.5), 3.12 (0.4-24.9) and
2.5 (0.2-19.7), respectively. The low number of non-
smokers did not allow performing risk analyses for any
of the genotype groups.
Discussion
This study was designed to determine whether genetic
polymorphisms in the CYP1A1 gene, an activator of car-
cinogens present in tobacco smoke, could play a role in
the extremely high lung cancer incidence rate observed
in a rural region of Southern Spain.
Results show that the pattern of combinations of
mutations yielding the different CYP1A1 variant alleles
in the present study differs from that reported for Cau-
casians. Several Spanish populations have been shown in
the past particularities regarding the presence of poly-
morphisms in other CYP enzymes [28,29]. The reason
seems to be the occurrence of gene flow from North
Africa across the Strait of Gibraltar that has caused
greater intermingling of gene pools than in most Eur-
opean-derived populations [30,31]. Thus, the
CYP1A1*2A mutant allele frequency in our population
was significantly greater than that observed in 2 pre-
vious large-scale studies with Caucasians [14,26]. It is
noteworthy that CYP1A1*2A i sf a rc o m m o n e ri nA f r i -
c a n s ,i nw h o mi t sf r e q u e n c yi so v e r2 0 %[ 1 4 ] ,s ot h a t
the aforementioned gene flow could be behind the high
frequency observed in our population. Furthermore, the
CYP1A1*2B and CYP1A1*2C frequencies in the controls
were lower than those reported for Caucasians (although
the differences did not reach statistical significance), but
mirrored those observed in Africans [14].
We then tried to determine whether these particulari-
ties regarding the presence of CYP1A1 variants were
translated into different susceptibilities to lung cancer in
our population. Most notably, subjects carrying the
462Val variant accounted for 12.7% of cases but only 3%
of controls. This polymorphism has consistently been
associated with lung cancer risk in Asian subjects
[32,33], while results in Caucasians have been more vari-
able [19-21,23,25,34]. The reason for the controversy in
the literature seems to be smoking, since the mutation
is believed to be important among light- and non-smo-
kers but not among heavy-smokers [19,20,23,35].
A limitation of the present study was the low number
of nonsmokers found among patients, which, for
instance, precluded a full assessment of the aforemen-
tioned interaction between smoking and the Ile462Val
Table 2 Distribution of CYP1A1 alleles in cases and
controls.
Allele Controls, N (%) Cases, N (%) OR (CI) p value
CYP1A1*1 452 (85.3) 168 (81.6) 1.0 (Ref.)
CYP1A1*2A 45 (8.5) 11 (5.3) 0.62 (0.3-1.2) 0.20
CYP1A1*2B 7 (1.3) 12 (5.8) 4.59 (1.4-12.6) < 0.01
CYP1A1*2C 1 (0.2) 1 (0.5) Nc
CYP1A1*3 2 (0.4) 2 (1) Nc
CYP1A1*4 23 (4.3) 12 (5.8) 1.32 (0.7-2.9) 0.29
N: Number of alleles
OR (CI): Odds ratio with 95% confidence interval
nc: Non-calculable
Table 3 CYP1A1 genotype frequencies observed.
Controls Cases
CYP1A1 genotype N (%) CI N (%) CI
ξ p
*1/*1 189 (71.3) 65.5-76.7 68 (66.0) 55.9-75.1 0.371
*1/*2A 44 (16.6) 12.3-21.7 10 (9.7) 2.6-8.7 0.102
*1/*2B 7 (2.6) 1.1-5.4 11 (10.7) 2.7-9.4 < 0.01
*1/*2C 1 (0.4) 0-2.1 1 (1.0) 0-5.3 nc
*1/*3 2 (0.7) 0.1-2.7 1 (1.0) 0-5.3 nc
*1/*4 20 (7.6) - 9 (8.7) 4.1-15.9 0.829
*2A/*4 1 (0.4) 0-2.1 1 (1.0) 0-5.3 nc
*2B/*3 0 (0) - 1 (1.0) 0.5.3 nc
*4/*4 1 (0.4) 0-2.1 1 (1.0) 0.5.3 nc
Total 265 103
Because of rounding, percentages may not total 100.
N: Number of subjects
nc: non-calculable
ξ Pearson’s c
2 analysis
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our rural population, which made the median of pack-
years used to stratify the subjects into moderate and
heavy smokers extremely high (50). In comparison, the
median in a similar Swedish study was 21 [25]. Thus,
the vast majority of participants in the study were smo-
kers who had been exposed to high amounts of tobacco
smoke throughout their lifetimes. The lack of patients
with low exposure to tobacco smoke in our region was
probably also the reason why none of the 4 genotype
groups assessed showed significant ORs after stratifica-
tion by cumulative tobacco dose.
In the present study, there was a particularly marked
impact of the 462Val mutation on the susceptibility to
SCLC, showing a significant OR of 6.97. This is coher-
ent with another case-control study that analyzed the
association of the Ile462Val polymorphism with several
lung cancer histological types, and found a slightly
higher OR (9.35) for SCLC [35]. Other reports, however,
indicate that the risk is higher for squamous-cell carci-
noma [19] (an association that was also observed in our
study) or non-small cell carcinomas [36]. It is of note,
however, that none of the two latter studies included
SCLC cases among the participants.
Another important finding of the present study was the
positive association of the Thr461Asn polymorphism
(CYP1A1*4 allele) with SCLC risk, since this variant was 3
times more frequent among these patients than in the
control group (OR = 8.33). This is the first time to our
knowledge that this allele has been related to high lung
cancer risk in a Caucasian population, since similar results
have only been observed in Indians [37], African-Ameri-
cans [38] or Hispanics [39]. In Caucasians, Vineis et al.
recently detected a positive allele-disease association, but
only where the variant occurred in combination with a
number of other CYP1A1 and GST polymorphisms [21].
Unlike our findings for the Ile462Val and Thr461Asn
polymorphisms, the results showed no association of the
MspI polymorphism (CYP1A1*2A allele) with lung can-
cer, which is consistent with earlier reports in Cauca-
sians [40-42]. Recent studies have found that an
increased risk may occur only in subjects homozygous
for the variant [20,43]. However, there were no
CYP1A1*2A homozygous carriers in our study popula-
tion, and therefore we cannot rule out a significant role
of this variant allele in the development of the disease
in our area until larger studies including homozygous
individuals are conducted.
Table 4 Odds ratios (OR)* and 95% confidence intervals (CI) for lung cancer risk according to CYP1A1 genotype
groups and stratification by histological types.
*1/*1 *1/*2
a *1/2B
*2B/*3
*1/*2C
*1/*4
*4/*4
*2A/*4
Controls, N (%) 189 (71.9) 44 (16.7) 8 (3.0) 22 (8.4)
All cases, N (%) 68 (66.7) 10 (9.8) 13 (12.7) 11 (10.8)
OR (CI) 1.0 0.51 (0.3-1.2) 4.51 (1.8-11.9) 1.29 (0.6-2.9)
p 0.18 < 0.01 0.29
Squamous-cell, N (%) 35 (71.4) 5 (10.2) 7 (14.3) 2 (4.1)
OR (CI) 1.0 0.51 (0.2-1.6) 5.01 (1.6-14.3) 0.49 (0.1-2.4)
p 0.37 < 0.01 0.40
Adenocarcinoma, N (%) 10 (66.7) 1 (6.7) 2 (13.3) 2 (13.3)
OR (CI) 1.0 0.41 (0.04-2.91)) 4.71 (0.8-27.3) 1.62 (0.3-7.7)
p 0.51 0.10 0.65
SCLC, N (%) 9 (60) - 2 (13.3) 4 (26.7)
OR (CI) 1.0 nc 6.97 (1.2-81.3) 8.33 (1.1-15.2)
p nc 0.04 0.04
LCLC, N (%) 14 (60.9) 4 (17.4) 2 (8.7) 3 (13)
OR (CI) 1.0 1.01 (0.3-3.1) 2.7 (0.5-14.6) 1.68 (0.4-5.2)
p 1 0.24 0.75
*ORs were adjusted for age, sex, and smoking (non/moderate/heavy), taking the CYP1A1*1/*1 genotype as reference. Genotype groups were generated as
described in the Methods section.
SCLC: Small-cell lung carcinoma.
LCLC: Large-cell lung carcinoma.
nc: non-calculable.
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as it made some subgroups too small to conduct any
statistical analysis. It also led to high upper limits of the
95% confidence intervals in the OR calculations. On the
other hand, it is of note that the hospital in which the
present study was carried out is the only cancer referral
centre in this high-incidence region. Therefore, that
allowed us to have access to all lung cancer patients, as
there were no more patients from this area than those
diagnosed and treated at this facility.
Conclusions
In summary, the results of this initial study show that 2
polymorphisms occurring at the CYP1A1 gene locus
(Ile462Val and Thr461Val) increase the risk to lung can-
cer in our population, and especially to SCLC. Moreover,
we have shown for the first time that Thr461Val
(CYP1A1*4) may be by itself a lung cancer risk factor in
Caucasians. However, there must be other factors besides
these polymorphisms, smoking, and the impact of a
family history of tumours contributing to maintaining
the observed uncommonly high lung cancer incidence. A
plausible hypothesis that would seem to merit additional
s t u d ym i g h tb et h ei n f l u e n c eo ft h em a s s i v eu s eo fp e s t i -
cides due to intensive agriculture, which is the main eco-
nomic activity in this area. Other factors, such as dietary
habits in the region and their interaction with other
genetic polymorphisms have recently been identified as
well [44]. Further studies are necessary to fully ascertain
the role of gene polymorphisms in high-incidence areas
such as that described in the present work.
Acknowledgements
The authors are grateful to Dr. Fernandez de los Rios Martin and the Clinical
Analyses Laboratory of the Merida Hospital for their interest and support in
carrying out the present study. The authors would also like to acknowledge
Mr. Robert Chatwin for English proofreading.
This work has been supported in part by grants PRI08A008 and GRU08120
from Junta de Extremadura, Consejeria de Economia, Comercio e
Innovacion, Merida (Spain); grant SCSS0750 from Junta de Extremadura,
Consejeria de Sanidad y Consumo, and grant PI071152 and 00/003401-02
from Plan Nacional de Investigación Científica, Desarrollo e Innovación
Tecnológica (I+D+I), Instituto de Salud Carlos III, Subdirección General de
Evaluación y Fomento de la Investigación
Author details
1Merida Hospital, Research Unit, 06008 Merida, Spain.
2Department of
Pharmacology, Medical School, University of Extremadura, Av. Elvas s/n,
06071 Badajoz, Spain.
Authors’ contributions
CSJ and MJ carried out the molecular genetic studies; AC conceived of the
study, participated in its design and performed the statistical analysis. JB and
JAC participated in the design of the study and helped with discussion of
clinical implications of genetic data. GG coordinated the study, participated
in its design and drafted the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 March 2010 Accepted: 30 August 2010
Published: 30 August 2010
References
1. Sanchez de Cos Escuin J, Riesco Miranda JA, Anton Martinez J, Diaz
Santamaria P, Marquez Perez L, Medina Gallardo JF, Tapia Regidor JC,
Rodriguez Blanco I: [Incidence of bronchopulmonary carcinoma in
Extremadura in 1998]. Arch Bronconeumol 2000, 36(7):381-384.
2. Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and
approaches to prevention. Lancet Oncol 2002, 3(8):461-469.
3. Guengerich FP, Shimada T: Oxidation of toxic and carcinogenic chemicals
by human cytochrome P-450 enzymes. Chem Res Toxicol 1991,
4(4):391-407.
4. Gelboin HV: Benzo[alpha]pyrene metabolism, activation and
carcinogenesis: role and regulation of mixed-function oxidases and
related enzymes. Physiol Rev 1980, 60(4):1107-1166.
5. Guengerich FP: Metabolic activation of carcinogens. Pharmacol Ther 1992,
54(1):17-61.
6. Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP:
Characterization of human lung microsomal cytochrome P-450 1A1 and
its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992,
41(5):856-864.
7. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M,
Alexandrov K, Rojas M, Saracci R, Giuntini C: Carcinogen metabolism in
human lung tissues and the effect of tobacco smoking: results from a
case–control multicenter study on lung cancer patients. Environ Health
Perspect 1992, 98:119-124.
8. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC,
Czerwinski M, Wood TG, Storeng R, Lubet RA, et al: Expression of CYP1A1
gene in patients with lung cancer: evidence for cigarette smoke-
induced gene expression in normal lung tissue and for altered gene
regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990,
82(16):1333-1339.
9. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL:
Positive correlation between high aryl hydrocarbon hydroxylase activity
and primary lung cancer as analyzed in cryopreserved lymphocytes.
Cancer Res 1982, 42(12):5030-5037.
10. Cuzick J, Routledge MN, Jenkins D, Garner RC: DNA adducts in different
tissues of smokers and non-smokers. Int J Cancer 1990, 45(4):673-678.
11. Phillips DH, Schoket B, Hewer A, Bailey E, Kostic S, Vincze I: Influence of
cigarette smoking on the levels of DNA adducts in human bronchial
epithelium and white blood cells. Int J Cancer 1990, 46(4):569-575.
12. Anttila S, Vainio H, Hietanen E, Camus AM, Malaveille C, Brun G, Husgafvel-
Pursiainen K, Heikkila L, Karjalainen A, Bartsch H: Immunohistochemical
detection of pulmonary cytochrome P450IA and metabolic activities
associated with P450IA1 and P450IA2 isozymes in lung cancer patients.
Environ Health Perspect 1992, 98:179-182.
13. Anttila S, Hietanen E, Vainio H, Camus AM, Gelboin HV, Park SS, Heikkila L,
Karjalainen A, Bartsch H: Smoking and peripheral type of cancer are
related to high levels of pulmonary cytochrome P450IA in lung cancer
patients. Int J Cancer 1991, 47(5):681-685.
14. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL,
Baranova H, Bathum L, Benhamou S, Boffetta P, et al: Metabolic gene
polymorphism frequencies in control populations. Cancer Epidemiol
Biomarkers Prev 2001, 10(12):1239-1248.
15. Georgiadis P, Topinka J, Vlachodimitropoulos D, Stoikidou M, Gioka M,
Stephanou G, Autrup H, Demopoulos NA, Katsouyanni K, Sram R, et al:
Interactions between CYP1A1 polymorphisms and exposure to
environmental tobacco smoke in the modulation of lymphocyte bulky
DNA adducts and chromosomal aberrations. Carcinogenesis 2005,
26(1):93-101.
16. Schwarz D, Kisselev P, Cascorbi I, Schunck WH, Roots I: Differential
metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by
human CYP1A1 variants. Carcinogenesis 2001, 22(3):453-459.
17. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, Yang IA,
Bowman RV, Fong KM: Genetic association study of CYP1A1
polymorphisms identifies risk haplotypes in nonsmall cell lung cancer.
Eur Respir J 2010, 35(1):152-159.
18. Lee KM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M,
Kiyohara C, Min S, Lan Q, Le Marchand L, Lin P, et al: CYP1A1, GSTM1, and
GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled
San Jose et al. BMC Cancer 2010, 10:463
http://www.biomedcentral.com/1471-2407/10/463
Page 6 of 7analysis among Asian populations. Cancer Epidemiol Biomarkers Prev 2008,
17(5):1120-1126.
19. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML,
Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, et al: Pooled analysis
of the CYP1A1 exon 7 polymorphism and lung cancer (United States).
Cancer Causes Control 2003, 14(4):339-346.
20. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D,
Cascorbi I, Clapper ML, Dolzan V, Haugen A, et al: Polymorphisms in
CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J
Epidemiol 2003, 32(1):60-63.
21. Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, Garte SJ,
Puntoni R, Rannug A, Strange RC, et al: Evidence of gene gene
interactions in lung carcinogenesis in a large pooled analysis.
Carcinogenesis 2007, 28(9):1902-1905.
22. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K: Genetic
polymorphism of CYP genes, alone or in combination, as a risk modifier
of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000,
9(1):3-28.
23. Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML,
Garte S, Haugen A, Hirvonen A, Anttila S, et al: CYP1A1 and GSTM1
genetic polymorphisms and lung cancer risk in Caucasian non-smokers:
a pooled analysis. Carcinogenesis 2003, 24(5):875-882.
24. Pisani P, Srivatanakul P, Randerson-Moor J, Vipasrinimit S, Lalitwongsa S,
Unpunyo P, Bashir S, Bishop DT: GSTM1 and CYP1A1 polymorphisms,
tobacco, air pollution, and lung cancer: a study in rural Thailand. Cancer
Epidemiol Biomarkers Prev 2006, 15(4):667-674.
25. Alexandrie AK, Nyberg F, Warholm M, Rannug A: Influence of CYP1A1,
GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on
lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers
Prev 2004, 13(6):908-914.
26. Cascorbi I, Brockmoller J, Roots I: A C4887A polymorphism in exon 7 of
human CYP1A1: population frequency, mutation linkages, and impact
on lung cancer susceptibility. Cancer Res 1996, 56(21):4965-4969.
27. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K: PCR detection of an A/G
polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res 1991,
19(17):4797.
28. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J: Differences in
CYP3A5*3 genotype distribution and combinations with other
polymorphisms between Spaniards and Other Caucasian populations.
Ther Drug Monit 2005, 27(6):819-821.
29. Agundez JA, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J:
Genetic basis for differences in debrisoquin polymorphism between a
Spanish and other white populations. Clin Pharmacol Ther 1994,
55(4):412-417.
30. Adams SM, Bosch E, Balaresque PL, Ballereau SJ, Lee AC, Arroyo E, Lopez-
Parra AM, Aler M, Grifo MS, Brion M, et al: The genetic legacy of religious
diversity and intolerance: paternal lineages of Christians, Jews, and
Muslims in the Iberian Peninsula. Am J Hum Genet 2008, 83(6):725-736.
31. Lucotte G, Gerard N, Mercier G: North African genes in Iberia studied by
Y-chromosome DNA haplotype 5. Hum Biol 2001, 73(5):763-769.
32. Nakachi K, Imai K, Hayashi S, Kawajiri K: Polymorphisms of the CYP1A1
and glutathione S-transferase genes associated with susceptibility to
lung cancer in relation to cigarette dose in a Japanese population.
Cancer Res 1993, 53(13):2994-2999.
33. Kihara M, Noda K: Risk of smoking for squamous and small cell
carcinomas of the lung modulated by combinations of CYP1A1 and
GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis
1995, 16(10):2331-2336.
34. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR,
Schwartz AG: CYP1A1 and CYP1B1 polymorphisms and risk of lung
cancer among never smokers: a population-based study. Carcinogenesis
2005, 26(12):2207-2212.
35. Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K,
Ohkawa A, Baba S, Morris BJ, Tsugane S, et al: Association of Ile462Val
(Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the
Asian population: further evidence from a case-control study in
Okinawa. Cancer Epidemiol Biomarkers Prev 1998, 7(5):413-417.
36. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM:
Risk of non-small cell lung cancer and the cytochrome P4501A1
Ile462Val polymorphism. Cancer Causes Control 2005, 16(5):579-585.
37. Shah PP, Singh AP, Singh M, Mathur N, Pant MC, Mishra BN, Parmar D:
Interaction of cytochrome P4501A1 genotypes with other risk factors
and susceptibility to lung cancer. Mutat Res 2008, 639(1-2):1-10.
38. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S: Lung cancer risk
and CYP1A1 genotype in African Americans. Carcinogenesis 1998,
19(5):813-817.
39. Gallegos-Arreola MP, Figuera-Villanueva LE, Troyo-Sanroman R, Morgan-
Villela G, Puebla-Perez AM, Flores-Marquez MR, Zuniga-Gonzalez GM:
CYP1A1 *2B and *4 polymorphisms are associated with lung cancer
susceptibility in Mexican patients. Int J Biol Markers 2008, 23(1):24-30.
40. D’Errico A, Malats N, Vineis P, Boffetta P: Review of studies of selected
metabolic polymorphisms and cancer. In Metabolic Polymorhisms and
Susceptibility to Cancer. Edited by: Vienis P, Malats N, Lang M, D’Errico A,
Caporaso N, Boffetta P. IARC Scientific publication No 148. Lyon:
International Agency for Research on Cancer; 1999:.
41. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF,
Hoover RN, Weston A, Harris CC: Lung cancer, race, and a CYP1A1 genetic
polymorphism. Cancer Epidemiol Biomarkers Prev 1993, 2(5):481-485.
42. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H: Point-
mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1
gene: lack of association with susceptibility to lung cancer in a Finnish
study population. Cancer Epidemiol Biomarkers Prev 1992, 1(6):485-489.
43. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML,
Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, et al: CYP1A1
T3801 C polymorphism and lung cancer: a pooled analysis of 2451
cases and 3358 controls. Int J Cancer 2003, 104(5):650-657.
44. Gervasini G, San Jose C, Carrillo JA, Benitez J, Cabanillas A: GST
polymorphisms interact with dietary factors to modulate lung cancer
risk: study in a high incidence area. Nutr Cancer 2010.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/463/prepub
doi:10.1186/1471-2407-10-463
Cite this article as: San Jose et al.: CYP1A1 gene polymorphisms
increase lung cancer risk in a high-incidence region of Spain: a case
control study. BMC Cancer 2010 10:463.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
San Jose et al. BMC Cancer 2010, 10:463
http://www.biomedcentral.com/1471-2407/10/463
Page 7 of 7